Adicet Bio Inc   (ACET)
Other Ticker:  
Price: $2.3800 $-0.02 -0.833%
Day's High: $2.54 Week Perf: -0.42 %
Day's Low: $ 2.26 30 Day Perf: -22.98 %
Volume (M): 1,323 52 Wk High: $ 8.16
Volume (M$): $ 3,149 52 Wk Avg: $3.27
Open: $2.45 52 Wk Low: $1.10

 Market Capitalization (Millions $) 102
 Shares Outstanding (Millions) 43
 Employees 50
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -143
 Cash Flow (TTM) (Millions $) -99
 Capital Exp. (TTM) (Millions $) 11

Adicet Bio Inc
Adicet Bio Inc is a clinical-stage biotechnology company that is at the forefront of developing cutting-edge therapies for cancer patients. The company was founded in 2015 and is headquartered in Menlo Park, California, with additional locations in Texas and Israel. Adicet Bio is a privately held company and has raised over $253 million in venture capital funding.

Adicet Bio is focused on developing novel immunotherapies that harness the power of the immune system to treat various forms of cancer. The company's platform technology uses ee T cells as a delivery vehicle for chimeric antigen receptor (CAR) and T cell receptor (TCR) therapies, enabling the cells to recognize and destroy cancer cells. The company's proprietary technology platform is based on over 20 years of research in the field of ee T cells.

Adicet Bio has a pipeline of several promising therapies in various stages of development, including ADI-001, which is being developed for the treatment of solid tumors. The drug is designed to target the B7-H3 antigen, which is overexpressed on several types of cancer cells, including breast, ovarian, bladder, and lung cancers. The therapy is currently in Phase 1 clinical trials.

Another promising therapy in Adicet Bio's pipeline is ADI-101, which is being developed for the treatment of non-Hodgkin's lymphoma (NHL). The drug incorporates the company's ee T cell platform technology and is designed to target the CD20 antigen, which is present on the surface of B cells. The therapy is currently in preclinical development.

Adicet Bio has a strong team of experienced executives and scientists who are dedicated to advancing innovative cancer therapies. The company is led by CEO Anil Singhal, who has over 20 years of experience in the biotechnology industry. The company's scientific team is led by Dr. Aya Jakobovits, who has a Ph.D. in Immunology from the Weizmann Institute of Science and has over 25 years of experience in the biotechnology industry.

In summary, Adicet Bio Inc is a clinical-stage biotechnology company that uses ee T cells as a delivery vehicle for innovative immunotherapies to treat cancer patients. The company has a strong pipeline of promising therapies in various stages of development and a dedicated team of experienced executives and scientists.

   Company Address: 200 Berkeley Street Boston 2116 MA
   Company Phone Number: 503-9095   Stock Exchange / Ticker: NASDAQ ACET
   ACET is expected to report next financial results on March 14, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Adicet Bio Inc

Headline: ACET Joins Ranks of Prominent Corporations by Announcing Impressive Third Quarter 2023 Effort2.

The Major Pharmaceutical Preparations industry has been closely watched by investors, with larger companies setting the tone for the sector. However, the spotlight has recently shifted to smaller corporations like ACET, which has published its financial results for the third quarter of 2023. With an operating loss of $-52.262 million, ACET faces the challenge of generating new revenue streams to stabilize its financial standing. While market interest in the company's operational capabilities remains limited, the significant increase in the shortfall compared to the previous year is a cause for concern.
ACET's Challenging Financial Performance:
ACET reported an operating loss of $-52.262 million for the third quarter of 2023, indicating a struggle to generate profits during this period. With stakeholders eagerly awaiting the emergence of new revenue streams, the company's financial future remains uncertain. ACET's deficient revenue has intensified considerably, with a shortfall of $-49.885 million in the third quarter of 2023, a significant increase from the $-21.996 million reported in the same quarter of 2022. This escalating trend highlights the urgent need for ACET to improve its financial position.

Adicet Bio Inc

Adicet Bio Inc Faces Operating Shortfall and Revenue Deficiency of $34.89 Million in Q2 2023

Adicet Bio Inc, a company operating in the Major Pharmaceutical Preparations sector, recently reported its financial results for the fiscal period ending June 30, 2023. The company's stock has experienced a decline of -0.8% over the past five trading days, compounding the year-to-date performance to -71.06%. However, despite these challenges, Adicet Bio Inc's stock trades 25.2% above its 52-week low. This article aims to interpret the financial results and speculate on how they may impact the company's future.
Operating Shortfall and Revenue Deficiency:
During the April to June 30, 2023 reporting cycle, Adicet Bio Inc disclosed an operating shortfall of $-34.89 million. This significant deficit raises concerns about the company's ability to cover its operational expenses effectively. Furthermore, the company experienced a net loss of $-32.403 million during the same period, which represents a substantial increase from the second quarter of 2022.

Adicet Bio Inc

Adicet Bio Inc Faces Sharp Profit Decline, with $-0.72 Shortfall per Share in Fiscal Q1 2023

Adicet Bio Inc, a clinical-stage biotechnology company, recently reported its fiscal first quarter of 2023 financial results. The company posted a shortfall per stock of $-0.72 per share, which was a significant decline from the $0.10 per share profit reported during the same period a year ago. Additionally, Adicet Bio reported a surge in the shortfall from $-0.64 per share in the prior financial reporting period.
Despite this significant decline in profitability, the company's revenue remained unchanged at $0.00 million from the corresponding financial reporting period a year before. The revenue was also sequentially the same, indicating that there was not much growth in the company's top-line performance.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com